Inflammatory Microenvironment Modulation of Alternative Splicing in Cancer: A Way to Adapt
- PMID: 32130703
- DOI: 10.1007/978-3-030-34025-4_13
Inflammatory Microenvironment Modulation of Alternative Splicing in Cancer: A Way to Adapt
Abstract
The relationship between inflammation and cancer has been long recognized by the medical and scientific community. In the last decades, it has returned to the forefront of clinical oncology since a wealth of knowledge has been gathered about the cells, cytokines and physiological processes that are central to both inflammation and cancer. It is now robustly established that chronic inflammation can induce certain cancers but also that solid tumors, in turn, can initiate and perpetuate local inflammatory processes that foster tumor growth and dissemination. Inflammation is the hallmark of the innate immune response to tissue damage or infection, but also mediates the activation, expansion and recruitment to the tissues of cells and antibodies of the adaptive immune system. The functional integration of both components of the immune response is crucial to identify and subdue tumor development, progression and dissemination. When this tight control goes awry, altered cells can avoid the immune surveillance and even subvert the innate immunity to promote their full oncogenic transformation. In this chapter, we make a general overview of the most recent data linking the inflammatory process to cancer. We start with the overall inflammatory cues and processes that influence the relationship between tumor and the microenvironment that surrounds it and follow the ever-increasing complexity of processes that end up producing subtle changes in the splicing of certain genes to ascertain survival advantage to cancer cells.
Keywords: Cancer; Inflammation; Signaling; Splicing; Tumor microenvironment.
Similar articles
-
Cancer and inflammation.Wiley Interdiscip Rev Syst Biol Med. 2017 Mar;9(2):10.1002/wsbm.1370. doi: 10.1002/wsbm.1370. Epub 2016 Dec 12. Wiley Interdiscip Rev Syst Biol Med. 2017. PMID: 27943646 Free PMC article. Review.
-
The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment.Front Endocrinol (Lausanne). 2022 Aug 22;13:929572. doi: 10.3389/fendo.2022.929572. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36072935 Free PMC article. Review.
-
Innate Immunity and Cancer Pathophysiology.Annu Rev Pathol. 2022 Jan 24;17:425-457. doi: 10.1146/annurev-pathmechdis-032221-115501. Epub 2021 Nov 17. Annu Rev Pathol. 2022. PMID: 34788549 Free PMC article. Review.
-
Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.Front Immunol. 2018 Mar 20;9:563. doi: 10.3389/fimmu.2018.00563. eCollection 2018. Front Immunol. 2018. PMID: 29662489 Free PMC article. Review.
-
Semaphorin Signaling in Cancer-Associated Inflammation.Int J Mol Sci. 2019 Jan 17;20(2):377. doi: 10.3390/ijms20020377. Int J Mol Sci. 2019. PMID: 30658382 Free PMC article. Review.
Cited by
-
Anti-FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer.Cancer Sci. 2021 Feb;112(2):847-858. doi: 10.1111/cas.14767. Epub 2021 Jan 2. Cancer Sci. 2021. PMID: 33306856 Free PMC article.
-
Astragalin Inhibits the Proliferation and Migration of Human Colon Cancer HCT116 Cells by Regulating the NF-κB Signaling Pathway.Front Pharmacol. 2021 Apr 19;12:639256. doi: 10.3389/fphar.2021.639256. eCollection 2021. Front Pharmacol. 2021. PMID: 33953676 Free PMC article.
-
Alternative splicing event associated with immunological features in bladder cancer.Front Oncol. 2023 Jan 5;12:966088. doi: 10.3389/fonc.2022.966088. eCollection 2022. Front Oncol. 2023. PMID: 36686818 Free PMC article.
-
Predictive value of CT radiomics and inflammatory markers for pulmonary adenocarcinoma spread through air spaces.Am J Cancer Res. 2025 Feb 15;15(2):587-600. doi: 10.62347/UBDR6353. eCollection 2025. Am J Cancer Res. 2025. PMID: 40084350 Free PMC article.
-
Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer.Front Immunol. 2022 Jun 13;13:911902. doi: 10.3389/fimmu.2022.911902. eCollection 2022. Front Immunol. 2022. PMID: 35769470 Free PMC article.
References
-
- Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF, Powell DW (2004) Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res Off J Am Assoc Cancer Res 10:5870–5879. https://doi.org/10.1158/1078-0432.CCR-0431-03 - DOI
-
- Agrawal AA, Yu L, Smith PG, Buonamici S (2018) Targeting splicing abnormalities in cancer. Curr Opin Genet Dev 48:67–74. https://doi.org/10.1016/j.gde.2017.10.010 - DOI - PubMed
-
- Anil C, Goksel S, Gursoy A (2010) Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid Off J Am Thyroid Assoc 20:601–606. https://doi.org/10.1089/thy.2009.0450 - DOI
-
- Bellahcène A, Castronovo V, Ogbureke KUE, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212–226. https://doi.org/10.1038/nrc2345 - DOI - PubMed - PMC
-
- Boi F, Pani F, Mariotti S (2017) Thyroid autoimmunity and thyroid cancer: review focused on cytological studies. Eur Thyroid J 6:178–186. https://doi.org/10.1159/000468928 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical